CMPX

Compass Therapeutics, Inc. (CMPX) - Q3 2024 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended September 30, 2024. Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing antibody-based therapeutics targeting angiogenesis and the immune system. The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue: The company recognized $0.85 million in licensing revenue for the nine months ended September 30, 2024, derived from a milestone payment from Elpiscience Biopharmaceuticals for CTX-009. No revenue was recognized in the comparable 2023 period.
• Operating Expenses: Total operating expenses increased by $5.93 million (17%) year-over-year for the nine-month period. Research and Development (R&D) expenses rose $3.6 million, driven by clinical costs for the CTX-009 biliary tract cancer trial, partially offset by reduced manufacturing costs. General and Administrative (G&A) expenses increased $2.3 million due to personnel costs related to a CEO transition and higher stock-based compensation.
• Liquidity: Cash and cash equivalents increased to $36.8 million from $24.2 million at year-end 2023, while marketable securities decreased to $98.6 million from $128.2 million. Total liquid assets remain at approximately $135 million.
• Financing: In Q1 2024, the company raised $18.1 million in gross proceeds via an At-The-Market (ATM) offering. No ATM sales occurred in Q3 2024.

Outlook, Guidance, and Risks

• Clinical Developments:
  • CTX-009: The Phase 2 monotherapy trial in metastatic colorectal cancer (CRC) was discontinued after failing to meet pre-determined response criteria in the first stage. The company plans to initiate a new second-line trial combining CTX-009 with chemotherapy in mid-2025. The Phase 2/3 trial in biliary tract cancer (BTC) is fully enrolled, with top-line data expected in Q1 2025. The FDA granted Fast Track Designation for this indication in April 2024.
  • CTX-471: A combination study with Merck's KEYTRUDA was discontinued due to unexpected cytokine suppression. New biomarker data presented in November 2024 suggests NCAM as a potential selection marker; a new study design is being evaluated for initiation in mid-2025.
  • CTX-8371: The Phase 1a trial is ongoing; the second cohort was completed with no dose-limiting toxicities. The third cohort is planned for initiation by year-end 2024.
• Liquidity Outlook: Management expects current cash resources ($135 million) to fund operations and capital expenditures into the first quarter of 2027.
• Lease Commitment: In September 2024, the company signed a new lease extending its facility term to May 2031, adding 10,724 square feet of space commencing in May 2025. This resulted in a new right-of-use asset of $6.1 million.
• Risks: The company has an accumulated deficit of $349.7 million and expects to continue incurring significant losses. Future funding will likely require additional equity or debt financing, which may dilute shareholders. There is no assurance that product candidates will receive regulatory approval or achieve commercial viability.

Investor Verification Checklist

• Verify the timeline and design of the new CTX-009 second-line CRC trial planned for mid-2025 following the discontinuation of the monotherapy trial.
• Monitor the expected Q1 2025 top-line data release for the CTX-009 BTC Phase 2/3 trial.
• Confirm the company's cash burn rate and runway into Q1 2027, considering the increased lease obligations and ongoing clinical costs.
• Review the status of the CTX-471 biomarker study design and the timeline for its initiation in mid-2025.
• Assess the impact of the new facility lease on future operating expenses and cash flow requirements.